Celltrion Is Latest To Snag A US Stelara Rival
Steqeyma Becomes Seventh FDA-Approved Ustekinumab Biosimilar
The latest US challenger to Stelara now has an approval in hand, with Celltrion lining up to join the pack of ustekinumab biosimilars that will be launching next year.
